THE FUTURE OF IMMUNO-ONCOLOGY: COMBINATION TREATMENTS, NOV 14 (NEW YORK)
Recommended non-UChicago event: Immuno-oncology treatments have provided renewed hope to cancer patients. Combination treatments bring the promise of increased efficacy with manageable side effects. Recommended by Board Member Sarah Ghosh, AB'11
Norman Selby, Board of Trustees at Memorial Sloan Kettering, Executive Chairman of RealEndpoints and PAIGE.AI, former Senior Partner at McKinsey
Sophie Opdyke, VP, Immuno-Oncology Lead, Global Commercial Development at Pfizer
Umer Raffat, Managing Director at Evercore ISI Peter Bach, Director, Center for Health Policy and Outcomes at MSK
There will be opportunity to network with fellow alumni during this event. Light refreshments will be provided.
Registration required, $20 HBSHAA members, $40 non-members
When: 6:00pm - 8:00pm, Tuesday November 14th
Where: UJA Conference Center, 130 East 59th Street, Room 712
Sophie Opdyke, VP& Immuno-Oncology Lead - Global Commercial Development, Pfizer. Responsible for developing and directing Pfizer’s strategies in the Immuno-Oncology area, leading commercial activities from pre-POC and pipeline assets in collaboration with R&D and championing BD opportunities in the field.
Umer Raffat, Senior Managing Director, Evercore ISI, M.S. International Health Economics, Harvard University. Covers large cap therapeutics, including Biotech, Pharmaceuticals-major and Specialty Pharmaceuticals. Ranked #1 in Institutional Investor’s Specialty Pharmaceuticals category for the last two years.
Peter Bach, Director of Memorial Sloan Kettering’s Center for Health Policy and Outcomes, B.A., Harvard University. Physician, epidemiologist, researcher, and respected healthcare policy expert whose work focuses on the cost and value of anticancer drugs. Dr. Bach is leading efforts to increase understanding of the US drug development process and develop new models for drug pricing that include value to patients as a critical component.
Norman Selby, MBA 1978, Chairman, Real Endpoints and PAIGE.AI, Board of Trustees at Memorial Sloan Kettering, former Senior Partner at McKinsey. Norman Selby has spent over 30 years in the healthcare world in a variety of consulting, managerial, investor and Board roles. He is also on the Board of Directors of Infinity Pharmaceuticals (INFI), a leading public biotech oncology company, Merz Group GmbH, a global specialty pharma company based in Frankfurt, Germany, and Metamark Genetics, a leading prostate cancer diagnostics company.